Cigna Group CEO David Cordani told investors the company expected pressure in its pharmacy benefit segment as it makes concessions to hold onto big clients and begins to phase out some drug rebates.

Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines in the third quarter, adding to challenges the drugmaker is facing as it prepares for the loss of its star cancer drug Keytruda.

Bristol Myers Squibb Co. raised its revenue outlook for the year after newer medicines outperformed expectations, easing pressure on its portfolio of aging blockbusters.

Biogen Inc. cut its full-year profit guidance on higher costs from deals the company has been doing to offset the decline of its aging multiple sclerosis drugs.

Character.AI’s announcement that it will ban users under 18 from conversing with chatbots is generating questions about the company’s planned age verification process and potentially broader chatbot harms, even as child safety advocates praised the move.

One of US President Donald Trump’s first actions against China following his re-election was to impose a 10% tariff on Chinese imports, punishing Beijing for what he described as its failure to curb illegal exports of fentanyl and the chemicals used to make it.